➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 5,792,795

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,792,795 protect, and when does it expire?

Patent 5,792,795 protects EPANOVA and is included in one NDA.

This patent has thirty patent family members in twenty-three countries.

Summary for Patent: 5,792,795
Title: Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
Abstract:Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).
Inventor(s): Buser; Thomas (Ziefen, CH), Camporesi; Emilio P. (Ziefen, CH)
Assignee: Tillotts Pharma AG (Ziefen, CH)
Application Number:08/687,329
Patent Claim Types:
see list of patent claims
Use; Compound; Dosage form;

Drugs Protected by US Patent 5,792,795

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,792,795

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9509764May 15, 1995
PCT Information
PCT FiledMay 13, 1996PCT Application Number:PCT/EP96/02038
PCT Publication Date:November 21, 1996PCT Publication Number: WO96/36329

International Family Members for US Patent 5,792,795

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 294575   Start Trial
Australia 5895596   Start Trial
Australia 702692   Start Trial
Brazil 9608785   Start Trial
Canada 2221356   Start Trial
China 1104237   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.